Evidence and Values: Requirements for Public Reimbursement of Drugs for Rare Diseases - a Case Study in Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 21, 2009

Evidence and Values: Requirements for Public Reimbursement of Drugs for Rare Diseases - a Case Study in Oncology



Conclusion:

There should be a greater commitment by reimbursement agencies to a fair and transparent decisionmaking process with appropriate community input. Criteria should be developed to validate surrogate
markers for rare diseases. It should also be acknowledged that the traditional measures of benefit in
economic studies do not incorporate all elements of social value.
The need should be recognized to balance equity with an efficient use of resources.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.